These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 29229600)

  • 1. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
    Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
    J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
    Flanagan JM; Wilson A; Koo C; Masrour N; Gallon J; Loomis E; Flower K; Wilhelm-Benartzi C; Hergovich A; Cunnea P; Gabra H; Braicu EI; Sehouli J; Darb-Esfahani S; Vanderstichele A; Vergote I; Kreuzinger C; Castillo-Tong DC; Wisman GBA; Berns EM; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2017 May; 23(9):2213-2222. PubMed ID: 27663594
    [No Abstract]   [Full Text] [Related]  

  • 7. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
    Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
    Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
    Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
    Shang S; Yang J; Jazaeri AA; Duval AJ; Tufan T; Lopes Fischer N; Benamar M; Guessous F; Lee I; Campbell RM; Ebert PJ; Abbas T; Landen CN; Difeo A; Scacheri PC; Adli M
    Cancer Res; 2019 Sep; 79(18):4599-4611. PubMed ID: 31358529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylomic Signatures of High Grade Serous Ovarian Cancer.
    Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
    Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
    Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
    Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and bioinformatics analysis of the relationship between LAMA3 DNA methylation expression and platinum resistance and prognosis in epithelial ovarian cancer].
    Chen CX; Zhang YL; Huang YZ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2024 Jun; 59(6):454-464. PubMed ID: 38951081
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
    Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.